Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (NASDAQ: CRSP) has already accomplished something most gene-editing companies are still trying to do: get a CRISPR-based medicine approved and onto the market. Now it has to prove it can build a business around the technology.

That starts with Casgevy, the gene-edited treatment for sickle cell disease developed with Vertex Pharmaceuticals (NASDAQ: VRTX). Casgevy generated $76 million in Q2 2026 revenue, up 78% sequentially and 151% year over year. It's now approved in 39 countries, and the FDA recently expanded its U.S. label to children as young as 2.

CRISPR Therapeutics receives 40% of Casgevy's profits and costs, while Vertex handles commercialization and manufacturing. That's a good foundation. But five years from now, I suspect Casgevy won't be the primary reason you'll want to own the stock.

The pipeline could become much more important

The program I'm watching most closely is CTX310, which uses CRISPR to edit a gene called ANGPTL3 inside the body. If you're unfamiliar, ANGPTL3 helps regulate cholesterol and triglycerides, two major contributors to cardiovascular disease. And unlike Casgevy, which requires doctors to remove a patient's cells, edit them outside the body, and return them after intensive conditioning, CTX310 is delivered through a single intravenous infusion.

Image source: Getty Images.

The results have been impressive. At the highest dose tested in a phase 1 study, CTX310 produced average reductions of 53% in LDL cholesterol and 48% in triglycerides. Those effects were sustained through one year following a single treatment.

The numbers are encouraging, but this is still early-stage clinical research. CRISPR is currently evaluating CTX310 in phase 1b trials targeting severe hypertriglyceridemia and refractory hypercholesterolemia (two types of high blood fat levels). If those studies eventually show that one treatment can safely produce durable reductions in cholesterol and triglycerides, CTX310 could address a much larger population than Casgevy. And that's where this company starts getting really interesting.

There's more than one shot on goal

CRISPR Therapeutics isn't betting everything on cardiovascular disease. Take Zugo-cel, formerly CTX112, an off-the-shelf CAR-T therapy being tested across autoimmune diseases and blood cancers. The company has trials underway in diseases including lupus, systemic sclerosis, multiple sclerosis, and several other autoimmune disorders.

Earlier results have provided some reason for optimism. In a small group of lymphoma patients receiving the 600-million-cell dose, Zugo-cel produced a 90% overall response rate and 70% complete response rate.

Then there's CTX340 for difficult-to-control high blood pressure, CTX460 for alpha-1 antitrypsin deficiency (a disorder that increases the risk of developing lung and liver disease), CTX611 for preventing blood clots, and CTX213, an experimental cell-replacement treatment for type 1 diabetes.

To be sure, not all of these programs will work. But they don't have to. If just two or three eventually become commercially successful medicines, CRISPR Therapeutics could look dramatically different by 2031.

The balance sheet buys plenty of time

Biotech companies can have great pipelines and still destroy shareholders if they continually need to raise money. CRISPR Therapeutics is in a much better financial position.

The company finished June with approximately $2.36 billion in cash, cash equivalents, and marketable securities. That cash gives management plenty of room to advance multiple programs without immediately returning to shareholders for more capital.

CRISPR Therapeutics currently has a market capitalization of roughly $5.4 billion. With more than $2 billion in cash and one commercial product already on the market, you aren't paying an outrageous valuation for the pipeline. But you are paying for some success.

Where could the stock be in 2031?

Predicting an exact share price for CRISPR Therapeutics five years out doesn't make much sense. There are just too many clinical trials between now and then. But the potential upside is substantial.

If Casgevy continues to gain adoption while CTX310 progresses into late-stage development and Zugo-cel demonstrates convincing efficacy in autoimmune disease, CRISPR Therapeutics could easily become a $10 billion to $15 billion company by 2031.

From today's roughly $5.4 billion valuation, that implies the potential for the stock to roughly double or even triple, although future dilution could reduce the per-share return. Indeed, the potential downside is not trivial. A major safety issue with in vivo gene editing or failures across CTX310 and Zugo-cel could erase a significant portion of the company's current valuation. That's why you shouldn't treat CRISPR Therapeutics like a conventional growth stock.

That said, Casgevy has already demonstrated that CRISPR can move from a laboratory concept to an FDA-approved medicine. The next five years will determine whether CRISPR Therapeutics could repeat that success across cardiovascular disease, autoimmune disorders, cancer, and other major diseases. If it can, today's $5.4 billion valuation could eventually look surprisingly cheap.

Jeff Siegel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy.